History
Since its establishment in 2018, Unilever Biotech has always focused on innovative biopharmaceutical research and development, continuously making breakthroughs in core technology platform construction and product pipeline promotion.
2026
Landing in Hangzhou&Angel Round Financing
Ulike Biotech has landed in Binjiang District, Hangzhou, completing tens of millions of RMB in angel round financing and promoting preclinical research on long-acting peptide innovative drugs.
2025
Construction of technology platform
Established ZT long-acting peptide original technology platform, with multiple core patents authorized by countries such as China, the United States, and Europe, and laid out multiple pipelines for first-class new drugs.
2024
R&D team building
Establish a global biopharmaceutical research and development team, initiate candidate drug screening, and improve the intellectual property protection system.
2023
Incubation of underlying technologies
Complete the validation of the core technology of long-acting peptides, overcome the challenges of peptide drug formulation, and initiate the incubation of innovative drug projects.